a phase ii, single arm study of bgj398 in patients with advanced cholangiocarcinoma

Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Mutation

Summary: this is a multi-center, open label, single arm phase ii study evaluating bgj398 (infigratinib) anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with fibroblast growth factor receptor (fgfr) genetic alterations.

adult patients with histologically or cytologically confirmed advanced or metastatic cholangiocarcinoma with fgfr2 gene fusions or translocations or other fgfr genetic alterations have been enrolled. subjects must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/metastatic disease. subjects should have had evidence of progressive disease following their prior regimen or if prior treatment was discontinued due to toxicity must have continued evidence of measurable disease. up to approximately 160 adult patients over age 18, both male and female were planned for enrollment. three cohorts of subjects comprise the study population: cohort 1: subjects with fgfr2 gene fusions (ie, fusions or rearrangements \[formerly translocations\]). cohort 2: subjects with fgfr genetic alterations other than fgfr2 gene fusions or rearrangements. cohort 3: subjects with fgfr2 gene fusions or rearrangements who have received a prior fgfr inhibitor. all subjects received oral bgj398 (infigratinib), once-daily, on a three weeks on (21 days), one week off (7 days) schedule. one treatment cycle consists of 28 days. notes: cohort 1 was pre-specified as the primary analysis population. results of these analyses were previously disclosed (posted 22 june 2022). there were no additional efficacy or safety endpoints to assess in cohort 1 after primary completion (01 march 2021). cohorts 2 and 3 were added at protocol amendment (pa) 4 to support only exploratory efficacy objectives of the study. these cohorts were ongoing the time of primary completion (01 march 2021). after interim review of the data from these cohorts (as permitted by the protocol) only limited efficacy was observed and the sponsor terminated the study early. therefore, a formal efficacy analysis was not performed for cohorts 2 and 3. however, baseline characteristics and safety data were analyzed.

Eligibility criteria:
inclusion criteria: - adult patients with histologically or cytologically confirmed cholangiocarcinoma at the time of diagnosis. patients with cancers of the gallbladder or ampulla of vater are not eligible. - patients must have received at least one prior regimen containing gemcitabine with or without cisplatin for advanced/ metastatic disease. patient should have evidence of progressive disease following prior regimen, or if prior treatment discontinued due to toxicity must have continued evidence of measurable or evaluable disease. exclusion criteria: * prior or current treatment with a mek inhibitor (all cohorts), bgj398 (infigratinib) (all cohorts), or selective fgfr inhibitor (cohorts 1 and 2 only). * insufficient organ function * absolute neutrophil count (anc) \< 1,000/mm3 \[1.0 x 10\^9/l\] * platelets \< 75,000/mm3 \[75 x 10\^9/l\] * hemoglobin \< 109.0 g/dl * total bilirubin \> 1.5x upper limit of normal (uln) * aspartate aminotransferase/glutamic oxaloacetic transaminase (ast/sgot) and alanine aminotransferase/glutamic pyruvic transaminase (alt/sgpt) \> 2.5x uln (ast and alt \> 5x uln in the presence of liver metastases) * serum creatinine \> 1.5x uln and a calculated or measured creatinine clearance \< 45 ml/min * inorganic phosphorus outside of normal limits * total and ionized serum calcium outside of normal limits other protocol-defined inclusion/exclusion criteria may apply.

Keywords: cholangiocarcinoma, fgfr2 gene fusion, fgfr genetic alteration